Total Funding
54
52
Total FundingPost-IPO Equity raised
Growth Score
-14 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
154681
Opthea is a public Australian biotechnology company that develops therapies to treat vision-threatening eye diseases.
- Peter Lang: Chief Financial OfficerPast Role: Aerie Pharmaceuticals, Chief Financial Officer
- Megan Baldwin: Founder and Chief Innovation OfficerPast Role: Opthea, CEO, Managing Director
About the Company
Opthea Limited (formerly Circadian Technologies) is a public Australian biotechnology company developing novel biologic therapies for the treatment of eye diseases.
Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and VEGF-D, which cause blood vessels to grow and leak.
Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD).
